Pancreatic ductal adenocarcinoma is one of the most lethal human malignancies. Over ninety-four percent of patients diagnosed with this disease succumb to this cancer. The high density of stromal tissue and aggressive propensity for early metastasis makes this a difficult malignant disease to treat. Nanotechnology holds a promise both for increasing the early diagnosis of pancreatic ductal adenocarcinoma and for providing improved therapeutic options. Nanomaterials as vectors to deliver cytotoxic agents, radioisotopes, antibodies, and other targeted therapies holds great promise in improving the outcome of patients diagnosed with pancreatic malignancy. This thematic series will focus on nanomaterials as diagnostic and therapeutic vectors. An emphasis will be placed on the interaction of nanotechnology, cancer biology, and physical science to improve our understanding of basic processes.
Edited by: Steven A. Curley (Christus Trinity Mother Frances, USA)
Before submitting your manuscript, please ensure you have carefully read the submission guidelines for Cancer Nanotechnology. The complete manuscript should be submitted through the Cancer Nanotechnology submission system. To ensure that you submit to the correct thematic series please select the appropriate thematic series in the drop-down menu upon submission. In addition, indicate within your cover letter that you wish your manuscript to be considered as part of the thematic series on Pancreatic Cancer. All submissions will undergo rigorous peer review and accepted articles will be published within the journal as a collection.
Submissions will also benefit from the usual advantages of open access publication:
- Rapid publication: Online submission, electronic peer review and production make the process of publishing your article simple and efficient.
- High visibility and international readership in your field: Open access publication ensures high visibility and maximum exposure for your work - anyone with online access can read your article
- No space constraints: Publishing online means unlimited space for figures, extensive data and video footage
- Authors retain copyright, licensing the article under a Creative Commons license: articles can be freely redistributed and reused as long as the article is correctly attributed.
Sign up to article alerts to keep updated on articles published in Cancer Nanotechnology - including articles published in this thematic series!
2018 Journal Metrics
52 days to first decision for reviewed manuscripts only
47 days to first decision for all manuscripts
160 days from submission to acceptance
23 days from acceptance to publication
52 Altmetric mentions
- ISSN: 1868-6966 (electronic)
- ISSN: 1868-6958 (print)